Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 11/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804781 | 0.91 | CYP3A4 (0.51) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 | |
| SCHEMBL22804370 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 | |
| SCHEMBL22804696 | 0.81 | CYP2C19 (0.57) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 | |
| SCHEMBL22804442 | 0.76 | CYP3A4 (0.50) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 | |
| SCHEMBL22805291 | 0.74 | AKR1C3 (0.58) | USP2ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL2819013 | 0.73 | MEN1 (0.78) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 | |
| SCHEMBL5015647 | 0.73 | AKR1C3 (0.65) | CYP2C19USP2CYP2C9ALDH1A1MEN1 | |
| SCHEMBL23199735 | 0.73 | AKR1C3 (0.42) | CYP3A4CYP2C19USP2CYP1A2ALDH1A1 | |
| SCHEMBL31237127 | 0.72 | TSHR (0.44) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 | |
| SCHEMBL22396274 | 0.71 | USP2 (0.62) | CYP3A4CYP2C19HIF1AUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986896-B1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | CYP3A4 3752/4885CYP2C19 1096/4885HIF1A 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.